Search Results - "Lübbe, K"

Anti-hormonal maintenance treatment with or without the CDK4/6 inhibitor ribociclib after first line chemotherapy in hormone receptor positive/HER2 negative metastatic breast cancer: A phase II trial (AMICA) GBG 97 by Decker, T., Denkert, C., Lübbe, K., Müller, V., Mundhenke, C., Furlanetto, J., Schmidt, M., Thill, M., Tierbach, V., Seither, F., Loibl, S.

Get full text

Characteristics of patients with brain metastases from human epidermal growth factor receptor 2-positive breast cancer: subanalysis of Brain Metastases in Breast Cancer Registry by Laakmann, E., Witzel, I., Neunhöffer, T., Park-Simon, T.-W., Weide, R., Riecke, K., Polasik, A., Schmidt, M., Puppe, J., Mundhenke, C., Lübbe, K., Hesse, T., Thill, M., Zahm, D.-M., Denkert, C., Fehm, T., Nekljudova, V., Rey, J., Loibl, S., Müller, V.

“…Up to 40% of patients with metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer develop brain metastases (BMs). Understanding of…”
Get full text

A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE) by Schmidt, M., Lübbe, K., Decker, T., Thill, M., Bauer, L., Müller, V., Link, T., Furlanetto, J., Reinisch, M., Mundhenke, C., Hoffmann, O., Zahn, M.-O., Müller, L., Denkert, C., van Mackelenbergh, M., Fasching, P.A., Burchardi, N., Nekljudova, V., Loibl, S.

“…Stomatitis is one of the main reasons to discontinue everolimus in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor…”
Get full text

Long-term survival of breast cancer patients with brain metastases: subanalysis of the BMBC registry by Riecke, K., Müller, V., Neunhöffer, T., Park-Simon, T.-W., Weide, R., Polasik, A., Schmidt, M., Puppe, J., Mundhenke, C., Lübbe, K., Hesse, T., Thill, M., Wuerstlein, R., Denkert, C., Decker, T., Fehm, T., Nekljudova, V., Rey, J., Loibl, S., Laakmann, E., Witzel, I.

“…Up to 30% of metastatic breast cancer (BC) patients develop brain metastases (BM). Prognosis of patients with BM is poor and long-term survival is rare…”
Get full text

Skin-reducing Mastectomy with Primary Implant Reconstruction by Siggelkow, W, Lübbe, K, Gade, J, Kölbl, H, Schmidt, M, Böhm, D

“…We present a series of skin-sparing mastectomies (SSMs) with skin reduction and immediate breast reconstruction to treat large and ptotic breasts. The…”
Get full text

Chemotherapy for 70-Year-Old Women with Breast Cancer in Germany: A Survey by the German Breast Group by Barinoff, J, Traut, A, Bauerschlag, D, Bischoff, J, Herr, D, Lübbe, K, Lück, H-J, Maass, N, Mundhenke, C, Schmidt, M, Schwedler, K, Thill, M, Steffen, J, Loibl, S, von Minckwitz, G

“…Around half of all women in Germany with breast cancer are older than 65 and approximately one third of them is older than 70 years of age. In theory, the…”
Get full text

LBA19 A multicenter, randomized, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (mBC) (DESIREE) by Loibl, S., Schmidt, M., Lübbe, K., Decker, T., Thill, M., Bauer, L., Müller, V., Link, T., Furlanetto, J., Kümmel, S., Mundhenke, C., Hoffmann, O., Zahn, M-O., Müller, L., Denkert, C., van Mackelenbergh, M., Fasching, P.A., Burchardi, N., Nekljudova, V.

Get full text

170P Long-term survival of breast cancer patients with brain metastases: Subanalysis of the BMBC registry by Riecke, K., Laakmann, E., Neunhöffer, T., Park-Simon, T-W., Weide, R., Schmidt, M., Polasik, A., Puppe, J., Mundhenke, C., Lübbe, K., Hesse, T., Thill, M., Zahm, D-M., Denkert, C., Fehm, T., Nekljudova, V., Rey, J., Loibl, S., Müller, V., Witzel, I.

Get full text

160O Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer, TNBC) (PM(Cb)) for patients (pts) with high-risk early breast cancer (BC) by Schneeweiss, A., Möbus, V., Tesch, H., Klare, P., Denkert, C., Kast, K., Hanusch, C., Link, T., Untch, M., Jackisch, C., Blohmer, J-U., Fasching, P.A., Solbach, C., Huober, J., Rhiem, K.E., Nekljudova, V., Lübbe, K., Loibl, S.

Get full text

96O Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (T) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2+ breast cancer: Subgroup analysis from KATHERINE by Loibl, S., Huang, C-S., Mano, M.S., Mamounas, T.P., Geyer, C.E., Untch, M., von Minckwitz, G., Thery, J-C., Schwaner, I., Limentani, S., Loman, N., Lübbe, K., Chang, J.C., Hatschek, T., Tesarowski, D., Boulet, T., Wiese, C., Song, C., Wolmark, N.

Get full text

149P Predicting prognosis of breast cancer patients with brain metastases in the BMBC registry: Comparison of three different prognostic scores by Riecke, K., Mueller, V., Neunhöffer, T., Weide, R., Schmidt, M., Park-Simon, T-W., Mundhenke, C., Polasik, A., Hesse, T., Lübbe, K., Laakmann, E., Thill, M., Fasching, P., Denkert, C., Fehm, T., Nekljudova, V., Rey, J., Loibl, S., Witzel, I.

Get full text

364TiPAnti-hormonal maintenance treatment with or without the CDK4/6 inhibitor ribociclib after first line chemotherapy in hormone receptor positive/HER2 negative metastatic breast cancer: A phase II trial (AMICA) GBG 97 by Decker, T, Denkert, C, Lübbe, K, Müller, V, Mundhenke, C, Furlanetto, J, Schmidt, M, Thill, M, Tierbach, V, Seither, F, Loibl, S

Get full text

95MO Characteristics of patients with brain metastases from HER2-positive breast cancer by Laakmann, E., Witzel, I., Neunhöffer, T., Park-Simon, T-W., Weide, R., Riecke, K., Polasik, A., Schmidt, M., Puppe, J., Mundhenke, C., Lübbe, K., Hesse, T., Thill, M., Zahm, D-M., Denkert, C., Fehm, T., Nekljudova, V., Rey, J., Loibl, S., Mueller, V.

Get full text

Characteristics and clinical outcome of breast cancer patients with asymptomatic brain metastases by Laakmann, E., Witzel, I., Neunhöffer, T., Weide, R., Schmidt, M., Park-Simon, T.W., Möbus, V., Mundhenke, C., Polasik, A., Lübbe, K., Hesse, T., Riecke, K., Thill, M., Fasching, P.A., Denkert, C., Fehm, T., Nekljudova, V., Rey, J., Loibl, S., Müller, V.

Get full text

Abstract P5-16-01: A randomised phase III trial comparing two dose-dense, dose-intensified approaches (ETC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto) by Schneeweiss, A, Möbus, V, Tesch, H, Hanusch, C, Denkert, C, Lübbe, K, Huober, J, Klare, P, Kümmel, S, Untch, M, Kast, K, Jackisch, C, Ingold-Heppner, B, Thomalla, J, Blohmer, J-U, Rezai, M, Nekljudova, V, von Minckwitz, G, Loibl, S

“…Abstract This abstract was withdrawn by the authors…”
Get full text

Abstract OT1-03-08: DESIREE - A multicenter, randomized, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer by Loibl, S, Furlanetto, J, Barinoff, J, Bauerschlag, D, Herr, D, Lübbe, K, Maass, N, Müller, V, Mundhenke, C, Schmidt, M, Schwedler, K, Thill, M, Gkantiragas, I, Burchardi, N, von Minckwitz, G

“…Abstract Background: The BOLERO-2 study demonstrated a relevant benefit for patients who received everolimus in addition to exemestane in patients who…”
Get full text

Ruddy turnstones Arenaria interpres rapidly build pectoral muscle after raptor scares by J. van den Hout, Piet, Piersma, Theunis, Dekinga, Anne, K. Lubbe, Suzanne, Henk Visser, G.

“…To cope with changes in the environment, organisms not only show behavioural but also phenotypic adjustments. This is well established for the digestive tract…”
Get full text

Effect of dairy farm management on Swallow Hirundo rustica abundance in The Netherlands by Lubbe, Suzanne K., de Snoo, Geert R.

“…Capsule Dairy farm management methods have no influence on numbers of Swallow breeding pairs. Aim To identify differences in Swallow abundance between…”
Get full text

Abstract P3-10-12: Pilot Phase of the Randomized PlanB Trial: Prospective Comparison of Molecular Classification, Oncotype DX® and Clinical-Pathological Characteristics in Hormone-Receptor (HR) Positive Primary Breast Cancer by Gluz, O, Kreipe, H, Christgen, M, Salem, M, Clemens, M, Markmann, S, Liedtke, B, Barinoff, J, Aktas, B, Henschen, S, Lübbe, K, Shak, S, Baehner, R, Liedtke, C, Nitz, U, Harbeck, N

“…Abstract Background: Despite progress in adjuvant breast cancer (BC) treatment, overtreatment due to decisions based on conventional prognostic factors (lymph…”
Get full text

West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer by Nitz, Ulrike, Gluz, Oleg, Clemens, Michael, Malter, Wolfram, Reimer, Toralf, Nuding, Benno, Aktas, Bahriye, Stefek, Andrea, Pollmanns, Anke, Lorenz-Salehi, Fatemeh, Uleer, Christoph, Krabisch, Petra, Kuemmel, Sherko, Liedtke, Cornelia, Shak, Steven, Wuerstlein, Rachel, Christgen, Matthias, Kates, Ronald E, Kreipe, Hans H, Harbeck, Nadia

“…The West German Study Group PlanB trial evaluated an anthracycline-free chemotherapy standard (six cycles of docetaxel and cyclophosphamide [TC]) in the…”
Get full text